Oncternal Therapeutics (ONCT) Revenue & Revenue Breakdown
Oncternal Therapeutics Revenue Highlights
Oncternal Therapeutics Revenue by Period
Oncternal Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $1.49M | -65.47% |
| 2021-12-31 | $4.32M | 27.85% |
| 2020-12-31 | $3.38M | 39.18% |
| 2019-12-31 | $2.42M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | -100.00% |
| 2011-12-31 | $14.74M | -75.68% |
| 2010-12-31 | $60.61M | 311.49% |
| 2009-12-31 | $14.73M | 8.89% |
| 2008-12-31 | $13.53M | 89.84% |
| 2007-12-31 | $7.13M | -5.05% |
| 2006-12-31 | $7.50M | 98.44% |
| 2005-12-31 | $3.78M | 102.57% |
| 2004-12-31 | $1.87M | 100.00% |
| 2003-12-31 | - | 100.00% |
| 2002-12-31 | - | 100.00% |
| 2001-12-31 | - | 100.00% |
| 2000-12-31 | - | 100.00% |
| 1999-12-31 | - | - |
Oncternal Therapeutics generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Oncternal Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $569.00K | 91.58% |
| 2023-12-31 | $297.00K | 65.92% |
| 2023-09-30 | $179.00K | 68.87% |
| 2023-06-30 | $106.00K | -47.78% |
| 2023-03-31 | $203.00K | 18.71% |
| 2022-12-31 | $171.00K | -55.24% |
| 2022-09-30 | $382.00K | 100.00% |
| 2022-06-30 | $191.00K | -74.40% |
| 2022-03-31 | $746.00K | 34.17% |
| 2021-12-31 | $556.00K | -73.87% |
| 2021-09-30 | $2.13M | 141.00% |
| 2021-06-30 | $883.00K | 18.05% |
| 2021-03-31 | $748.00K | -52.90% |
| 2020-12-31 | $1.59M | 171.45% |
| 2020-09-30 | $585.00K | -6.10% |
| 2020-06-30 | $623.00K | 7.79% |
| 2020-03-31 | $578.00K | -21.47% |
| 2019-12-31 | $736.00K | 35.29% |
| 2019-09-30 | $544.00K | -19.29% |
| 2019-06-30 | $674.00K | 43.40% |
| 2019-03-31 | $470.00K | -1.47% |
| 2018-12-31 | $477.00K | 44.98% |
| 2018-09-30 | $329.00K | -78.45% |
| 2018-06-30 | $1.53M | 712.23% |
| 2018-03-31 | $188.00K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $-2.51M | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | -100.00% |
| 2012-06-30 | $1.64M | -10.39% |
| 2012-03-31 | $1.83M | 3.33% |
| 2011-12-31 | $1.77M | -12.76% |
| 2011-09-30 | $2.03M | 23.34% |
| 2011-06-30 | $1.65M | -82.30% |
| 2011-03-31 | $9.29M | 414.96% |
| 2010-12-31 | $1.80M | 39.27% |
| 2010-09-30 | $1.30M | 38.61% |
| 2010-06-30 | $935.00K | -98.35% |
| 2010-03-31 | $56.58M | 1438.67% |
| 2009-12-31 | $3.68M | 2.14% |
| 2009-09-30 | $3.60M | -5.81% |
| 2009-06-30 | $3.82M | 5.26% |
| 2009-03-31 | $3.63M | 21.11% |
| 2008-12-31 | $3.00M | -1.67% |
| 2008-09-30 | $3.05M | 1.36% |
| 2008-06-30 | $3.01M | -32.75% |
| 2008-03-31 | $4.47M | 133.33% |
| 2007-12-31 | $1.92M | - |
Oncternal Therapeutics generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Oncternal Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| KZR | Kezar Life Sciences | $7.00M | - |
| ABSI | Absci | $5.72M | $898.00K |
| ADTX | Aditxt | $645.18K | $44.28K |
| VCNX | Vaccinex | $570.00K | $232.00K |
| TARA | Protara Therapeutics | - | - |
| TIL | Instil Bio | - | - |
| PASG | Passage Bio | - | - |
| NLTX | Neurogene | - | - |
| ADVM | Adverum Bio | - | - |
| MNPR | Monopar Therapeutics | - | - |
| ONCT | Oncternal Therapeutics | - | - |
| SRZN | Surrozen | - | - |
| NUVB | Nuvation Bio | - | $1.44M |
| KTTA | Pasithea Therapeutics | - | - |
ONCT Revenue FAQ
What is Oncternal Therapeutics’s yearly revenue?
Oncternal Therapeutics's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $1.49M, representing a decrease of -65.47% compared to 2021. ONCT's yearly revenue for 2021 was $4.32M, representing an increase of 27.85% compared to 2020.
What is Oncternal Therapeutics’s quarterly revenue?
Oncternal Therapeutics's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $569K, a 91.58% increase from the previous quarter (Q4 2023), and a 180.30% increase year-over-year (Q1 2023). ONCT's quarterly revenue for Q4 2023 was $297K, a 65.92% increase from the previous quarter (Q3 2023), and a 73.68% increase year-over-year (Q4 2022).
What is Oncternal Therapeutics’s revenue growth rate?
Oncternal Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.